Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Avanir’s Alzheimer’s Agitation Drug Hits Primary Goal in PIII
March 26, 2019
- AstraZeneca Grabs All Global Fasenra Rights in Expanded Pact with Kyowa Kirin
March 26, 2019
- Vimpat IV Version Hits Japan Market: UCB, Daiichi Sankyo
March 26, 2019
- Ono Chief Recounts Long and Winding Road of Opdivo Development, Thanks Kyoto Univ. Professor
March 25, 2019
- JCR Files Temcell for Epidermolysis Bullosa
March 25, 2019
- Japan Biosimilar Market Could Grow Like in Europe If Incentives Improved: Sandoz Japan Chief
March 25, 2019
- Eisai Going Ahead with Global PIII for BAN2401 despite Aducanumab Setback
March 25, 2019
- Analyst Says Drug Makers Can’t Recoup Investment in Overcompetitive Oncology Arena
March 22, 2019
- Biogen/Eisai’s Aducanumab Fails, Dashing Hopes in Alzheimer’s Field
March 22, 2019
- J-TEC Submits Japan’s First Regenerative Medicine Product in Ophthalmology Field
March 22, 2019
- Mitsubishi Tanabe Sets Up Sales Subsidiary in Malaysia for Independent Marketing
March 22, 2019
- Takeda Taps Neuro-Psychiatric Expert Kajii as T-CiRA Chief
March 22, 2019
- Nippon Shinyaku Licenses Dravet Syndrome Treatment from Zogenix
March 22, 2019
- Chugai, SRL Link Up for Cancer Gene Mutation Tests
March 22, 2019
- Medipal Holdings Invests in Belgium’s Cell Therapy Developer
March 22, 2019
- Gilead Set to Duplicate Biktarvy Success in Japan with New Stand-Alone HIV Sales Force
March 20, 2019
- Daiichi Sankyo’s Edoxaban Demonstrates Efficacy, Safety in AF Patients Undergoing Catheter Ablation
March 20, 2019
- Ono Files Multiple Myeloma Treatment Kyprolis for Once-Weekly Administration Regimen
March 20, 2019
- Servier, Oncodesign Join Forces to Develop Parkinson’s Disease Treatments
March 20, 2019
- NapaJen, Astellas Form Oligonucleotide Research Collaboration
March 19, 2019
ページ
Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…